Attached files
file | filename |
---|---|
EX-99.1 - Eloxx Pharmaceuticals, Inc. | v171620_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
_______________________________
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): January 14,
2010
Senesco Technologies,
Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware | 001-31326 | 84-1368850 |
(State
or Other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
303
George Street, Suite 420, New Brunswick, New Jersey
|
08901 |
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(732) 296-8400
|
(Registrant's
telephone number,
including
area code)
|
Not applicable
|
(Former
Name or Former Address, if Changed Since Last Report)
|
Check the
appropriate box below if the Form 8-K is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following
provisions:
o Written communications
pursuant to Rule 425 under the Securities Act
(17 CFR 230.425).
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12).
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)).
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)).
Item
3.01 Notice of Delisting
or Failure to Satisfy a Continued Listing Rule or Standard;Transfer of
Listing.
On
January 14, 2010, Senesco Technologies, Inc. (the “Company” or “Senesco”)
received notice from the NYSE Amex LLC
(“NYSE”) stating that the exchange had accepted the Company’s compliance plan
and granted it an extension until April 29, 2011 to regain compliance with the
NYSE’s continued listing standards. As previously disclosed, Senesco
is not in compliance with Section 1003(a)(iii) of the NYSE company guide with
stockholder’s equity of less than $6,000,000 and losses from continuing
operations and/or net losses in its five most recent fiscal
years. Based on this, the Company submitted a plan advising the NYSE
of action it will take, that the Company believes would bring Senesco into
compliance with the NYSE’s continued listing standards by the end of the
extension period.
During
the extension period, the Company remains subject to periodic review by NYSE
Staff. Failure to make progress consistent with the plan or to regain
compliance with the continued listing standards by the end of the extension
period could result in Senesco being delisted from the NYSE.
Item
9.01 Financial Statements
and Exhibits.
(d)
Exhibits.
Exhibit
No.
|
Description
|
99.1
|
Press
Release, dated January 19, 2010 relating to the receipt of the NYSE Amex
LLC notification.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
SENESCO
TECHNOLOGIES, INC.
|
|||
Dated:
January 19, 2010
|
By:
|
/s/ Jack Van Hulst | |
Name:
Jack Van Hulst
|
|||
Title:
President and Chief Executive
Officer
|